Cargando…
C-Abl Inhibitor Imatinib Enhances Insulin Production by β Cells: C-Abl Negatively Regulates Insulin Production via Interfering with the Expression of NKx2.2 and GLUT-2
Chronic myelogenous leukemia patients treated with tyrosine kinase inhibitor, Imatinib, were shown to have increased serum levels of C-peptide. Imatinib specifically inhibits the tyrosine kinase, c-Abl. However, the mechanism of how Imatinib treatment can lead to increased insulin level is unclear....
Autores principales: | Xia, Chang-Qing, Zhang, Pengcheng, Li, Shiwu, Yuan, Lihui, Xia, Tina, Xie, Chao, Clare-Salzler, Michael J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023982/ https://www.ncbi.nlm.nih.gov/pubmed/24835010 http://dx.doi.org/10.1371/journal.pone.0097694 |
Ejemplares similares
-
Defining the target and the effect of imatinib on the filarial c-Abl homologue
por: O’Connell, Elise M., et al.
Publicado: (2017) -
Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells
por: Okabe, Seiichi, et al.
Publicado: (2014) -
Imatinib may be ABL to improve anti-angiogenic therapy
por: Raimondi, Claudio, et al.
Publicado: (2015) -
ABL1 and ABL2 promote medulloblastoma leptomeningeal dissemination
por: Jones, Jill K, et al.
Publicado: (2023) -
Crystal Structures of ABL-Related Gene (ABL2) in Complex with Imatinib, Tozasertib (VX-680), and a Type I Inhibitor of the Triazole Carbothioamide Class
por: Salah, Eidarus, et al.
Publicado: (2011)